Press Releases - Sami Labs

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sabinsa Founder Dr. Muhammed Majeed Publishes Book on Reductive Metabolites of Curcuminoids

Sabinsa to Feature Tinofolin® Nootropic, Livinol™ for Liver Health & Weight Control, and Starmeric™ Turmeric-Derived Prebiotic at Supplyside West

Pilot Study Published Examining Curcumin C3 Complex® and BioPerine® With Taurine as Treatment for Hepatocellular Carcinoma

Study Shows Inhibitory Effect of Curcumin C3 Complex® and BioPerine® Combination on Malignant Mesothelioma Cells

Sabinsa Opens Sales Office in Poland to Serve Eastern Europe

Sabinsa’s Four Indian Manufacturing Sites Achieve FSSC 22000 Certification

ABOUT SAMI LABS

HEADQUARTERS

CERTIFICATES

CONTACT US